Empowering Healthier Lives
Atrium Innovations is recognized around the world as an innovative leader in the development, manufacturing, and commercialization of science-based nutritional health products.
Atrium Innovations is headquartered in Montreal, Canada and we have offices and manufacturing plants around the globe. We are a vertically integrated company with seven manufacturing facilities in the U.S., Canada, Europe and Argentina.
Empowering healthier lives.
Be a global leader in vitamins, minerals and supplements with the largest and fastest growing brands in the markets and channels in which we choose to distribute, with a proven reputation for premium-quality, science-based, professionally recognized products.
Our History at a glance
June Peter Luther appointed as President and CEO
February Acquisition of Atrium Innovations by a group backed by the Permira funds
October Atrium Innovations acquires a controlling interest in Mucos Pharma CZ s.r.o., the exclusive distributor of Wobenzym® products in Central and Eastern Europe.
August Acquisition of Enzimas S.A.
April Acquisition of Robert & Fils (Québec) Inc.
December Acquisition of Seroyal
March Acquisition of Trophic Canada
September Acquisition of Garden of Life
January Acquisition of the Wobenzym© family of products manufacturing facility (EAB Enzym‐Arzneimittel‐Berlin GmbH)
December Acquisition of Nutri-Health and its family of brands
September Acquisition of the AOV brand (Orthos Europe BV)
May Atrium Innovations divests its Active Ingredients & Specialty Chemicals Division
February Acquisition of Orthica and its family brands (Multicare B.V.)
July Acquisition of Wobenzym© and its family of brands (Mucos Emulsions GMBH)
May Atrium Biotechnologies Inc. changes its name to Atrium Innovations Inc.
January Acquisition of a liquid-filled capsule manufacturing facility (AquaCap) and its Caplique technology
October Atrium Biotechnologies is spun-off completely from
September Acquisition of Douglas Laboratories Canada
December Acquisition of Douglas Laboratories
March Atrium becomes a publicly-traded company with an Initial Public Offering
March Acquisition of Pure Encapsulations, Inc.
Two private placements with SGF Soquia Inc. and Fonds de solidarité des travailleurs du Québec (FTQ)
December Atrium Biotechnologies Inc. is established as a separate subsidiary of Æterna Laboratories Inc. (now known as AEterna Zentaris Inc.). Both companies where founded by brothers, Eric and Luc Dupont.